Employment |
No Relationships to Disclose |
|
|
Leadership |
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests |
No Relationships to Disclose |
|
|
Honoraria |
No Relationships to Disclose |
|
|
Consulting or Advisory Role |
Company: Bristol-Myers Squibb |
Recipient: You |
Company: Merck |
Recipient: You |
Company: EMD Serono |
Recipient: You |
Company: BioNTech |
Recipient: You |
Company: Shattuck |
Recipient: You |
Company: Bayer |
Recipient: You |
Company: Debiopharm Group |
Recipient: You |
Company: Ipsen |
Recipient: You |
Company: Gilead Sciences |
Recipient: You |
Company: Bicara Therapeutics |
Recipient: You |
Company: BioNTech AG |
Recipient: You |
Company: Nektar |
Recipient: You |
Company: Istari |
Recipient: You |
Company: LLX Solutions |
Recipient: You |
Company: OncLive |
Recipient: You |
Company: Seagen |
Recipient: You |
Company: Kura |
Recipient: You |
Company: Mirati |
Recipient: You |
Company: Eisai |
Recipient: You |
Company: Exelixis |
Recipient: You |
Company: ITeos Therapeutics |
Recipient: You |
Company: Caladrius Biosciences |
Recipient: You |
Company: Coherus Biosciences |
Recipient: You |
Company: Surface |
Recipient: You |
Company: Merus |
Recipient: You |
Company: Adaptimmune |
Recipient: You |
Company: END Merck |
Recipient: You |
Company: Bristol-Myers Squibb/Roche |
Recipient: You |
Company: BioNTech SE |
Recipient: You |
Company: Journal of Clinical Oncology |
Recipient: You |
Company: Axiom Biotechnologies |
Recipient: You |
Company: Aptitude Health |
Recipient: You |
Company: EMD Serono |
Recipient: You |
Company: Bicara Therapeutics |
Recipient: You |
Company: Guidepoint Global |
Recipient: You |
Company: Coherus Biosciences |
Recipient: You |
Company: LLX Solutions |
Recipient: You |
Company: Abbvie |
Recipient: You |
Company: Pfizer |
Recipient: You |
Company: Brightly Network |
Recipient: You |
Company: Boxer Capital |
Recipient: You |
Company: Merus |
Recipient: You |
Company: EMD Serono |
Recipient: You |
Company: Takeda |
Recipient: You |
Company: Suzhou Liangyihui Network Technology |
Recipient: You |
Company: Sensei Biotherapeutics |
Recipient: You |
|
Speakers' Bureau |
No Relationships to Disclose |
|
|
Research Funding |
Company: Bristol-Myers Squibb |
Recipient: Your Institution |
Company: Genocea Biosciences |
Recipient: Your Institution |
Company: Cullinan |
Recipient: Your Institution |
Company: Genentech |
Recipient: Your Institution |
Company: Agenus |
Recipient: Your Institution |
Company: Kura |
Recipient: Your Institution |
Company: Seagen |
Recipient: Your Institution |
Company: Abbvie |
Recipient: Your Institution |
Company: BioNTech SE |
Recipient: Your Institution |
Company: NRG Oncology |
Recipient: Your Institution |
Company: INVAX |
Recipient: Your Institution |
Company: Merus |
Recipient: Your Institution |
Company: Gilead Sciences |
Recipient: Your Institution |
Company: Merck |
Recipient: Your Institution |
Company: Roche |
Recipient: Your Institution |
|
Patents, Royalties, Other Intellectual Property |
Please describe: PCT/US2022/023911
pending
Board of Regents, The University of Texas System
|
Recipient: You |
|
Expert Testimony |
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses |
No Relationships to Disclose |
|
|
Other Relationship |
No Relationships to Disclose |
|
|
(OPTIONAL) Uncompensated Relationships |
No Relationships to Disclose |
|
|
(OPTIONAL) Open Payments Link |
No Relationships to Disclose |
|
|